The role of host and viral translation factors during HCMV infection

宿主和病毒翻译因子在 HCMV 感染过程中的作用

基本信息

  • 批准号:
    8837861
  • 负责人:
  • 金额:
    $ 2.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-25 至 2017-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): All viruses share the requirement for host ribosomes for the synthesis of viral proteins. Viral mRNAs must compete with host messages for access to the host translation machinery, and therefore viruses have evolved multiple mechanisms to ensure that viral mRNAs are preferentially translated during infection. Many viruses inhibit host protein synthesis, presumably to provide greater resources for the translation of viral mRNAs. Human cytomegalovirus (HCMV) is unusual in that infection does not inhibit host protein synthesis. How do HCMV mRNAs effectively compete with host mRNAs for access to ribosomes? The recruitment of ribosomes to mRNAs is facilitated by translation initiation factors. Control of translation initiation factor expression and activity is a key regulatory step in mRNA translation. Previous studies have shown that HCMV induces the expression and activity of the eIF4F translation initiation complex, which is required for the translation of capped mRNAs. As most mRNAs are capped, the eIF4F complex is required for the translation of most host mRNAs. However our preliminary studies suggest that, surprisingly, inhibiting host signaling pathways that control eIF4F activity has minimal impact on HCMV mRNA translation. This suggests that the mechanism of translation initiation on viral mRNAs is fundamentally different from that used by host mRNAs. Our data suggests that the HCMV TRS1 protein (pTRS1) acts as a viral translation initiation factor that replaces the function of the eIF4F complex on viral mRNAs. These data lead us to our overall hypothesis that viral proteins direct the loading of ribosomes onto HCMV mRNAs through a process that does not require the eIF4F complex. This hypothesis shifts the paradigm for the translation of HCMV mRNAs, from one in which host proteins are the critical regulatory factors, to one in which HCMV proteins are the primary determinants of viral protein synthesis. We test our hypothesis in two specific aims. In Aim1 we use a combination of genetic, chemical, and genomics approaches to define the role of the eIF4F complex and it subunits in HCMV mRNA translation throughout infection. Aim 2 tests our hypothesis that pTRS1 is a viral translation initiation factor that substitutes for the eIF4F complex during the translation of viral mRNAs. We will determine how i) pTRS1 associates with the translation machinery, ii) the full complement of mRNAs bound by pTRS1 during infection and iii) the role of pTRS1 interaction with the host translation machinery in HCMV mRNA translation and replication. Statement of
性状(由申请方提供):所有病毒都需要宿主核糖体来合成病毒蛋白。病毒mRNA必须与宿主信息竞争进入宿主翻译机制,因此病毒已经进化出多种机制来确保病毒mRNA在感染期间优先翻译。许多病毒抑制宿主蛋白质合成,可能是为了提供更多的资源用于病毒mRNA的翻译。人巨细胞病毒(HCMV)是不寻常的,因为感染不抑制宿主蛋白质合成。HCMV mRNAs如何有效地与宿主mRNAs竞争进入核糖体?翻译起始因子促进核糖体向mRNA的募集。翻译起始因子的表达和活性的控制是mRNA翻译的关键调控步骤。先前的研究表明,HCMV诱导eIF4F翻译起始复合物的表达和活性,这是加帽mRNA翻译所必需的。由于大多数mRNA都是加帽的,因此大多数宿主mRNA的翻译都需要eIF4F复合物。然而,我们的初步研究表明,令人惊讶的是,抑制控制eIF4F活性的宿主信号传导途径对HCMV mRNA翻译的影响最小。这表明病毒mRNA的翻译起始机制与宿主mRNA的翻译起始机制根本不同。我们的数据表明,HCMV TRS 1蛋白(pTRS 1)作为病毒翻译起始因子,取代病毒mRNA上的eIF4F复合物的功能。这些数据使我们得出了我们的总体假设,即病毒蛋白通过不需要eIF4F复合物的过程指导核糖体加载到HCMV mRNA上。这一假说改变了HCMV mRNA翻译的范式,从宿主蛋白是关键调控因子转变为HCMV蛋白是病毒蛋白合成的主要决定因素。我们在两个特定的目标测试我们的假设。在Aim1中,我们使用遗传学、化学和基因组学方法的组合来确定eIF4F复合物及其亚基在整个感染过程中HCMV mRNA翻译中的作用。目的2验证我们的假设,即pTRS 1是一种病毒翻译起始因子,在病毒mRNA的翻译过程中取代了eIF4F复合物。我们将确定i)pTRS 1如何与翻译机制相关联,ii)感染期间pTRS 1结合的mRNA的完整补体,以及iii)pTRS 1与宿主翻译机制在HCMV mRNA翻译和复制中的相互作用。表

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nathaniel J Moorman其他文献

Nathaniel J Moorman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nathaniel J Moorman', 18)}}的其他基金

Hybrid Sequencing to Define the Full-Length Transcriptome of Double Stranded DNA Viruses
混合测序定义双链 DNA 病毒的全长转录组
  • 批准号:
    9092162
  • 财政年份:
    2016
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    9180060
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    8421184
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    8968812
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    10456099
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    8586252
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    10199922
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:
The role of host and viral translation factors during HCMV infection
宿主和病毒翻译因子在 HCMV 感染过程中的作用
  • 批准号:
    9668255
  • 财政年份:
    2012
  • 资助金额:
    $ 2.27万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 2.27万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 2.27万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 2.27万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 2.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 2.27万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 2.27万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 2.27万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 2.27万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 2.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 2.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了